| Features: |
Chemiluminescent, non-radioactive format
Higher throughput, 96 test size
Sensitivity down to 10 pg/ml of PAR
|
| |
| Applications: |
Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
Monitoring the efficacy of PARP inhibitors on cellular PAR formation
Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
|
| |
| Components: |
Part # |
Component |
Size |
| |
4500-096-01 |
PAR Standard, 6.25 pg/µl |
50 µl |
| |
4500-096-02 |
Blocking/Sample Buffer |
30 ml |
| |
4500-096-03 |
PAR Monoclonal Capture Antibody |
15 µl |
| |
4500-096-04 |
PAR Polyclonal Detecting Antibody |
30 µl |
| |
4500-096-05 |
Goat anti-Rabbit IgG-HRP |
30 µl |
| |
4500-096-06 |
Cell Lysis Reagent |
30 ml |
| |
4500-096-07 |
20% (w/v) SDS |
1 ml |
| |
4500-096-08 |
DNase I, 2 Units/µl |
30 µl |
| |
4500-096-09 |
100X Magnesium Cation |
500 µl |
| |
4500-096-10 |
Antibody Coating Solution |
10 ml |
| |
4500-096-11 |
Jurkat Cell Lysate Standard |
900 µl |
| |
4500-096-12 |
Antibody Diluent |
12 ml |
| |
4510-096-P |
White 96-stripwell plate and 5 sealers |
1 plate |
| |
4675-096-01 |
PeroxyGlow™ A |
6 ml |
| |
4675-096-02 |
PeroxyGlow™ B |
6 ml |
| |
| Storage: |
Components are stored at -80°C, -20°C, 4°C, and room temperature |
| |
| References: |
1. Kinders JK, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute Phase 0 Clinical Trials Team. 2008. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 14:6877-6885.
2. Cao WH, Wang X, Frappart L, Rigal D, Wang ZQ, Shen Y, Tong WM. 2007. Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients. Mutat Res 632:20-8.
3. Piper, A.A., A.Verma, J. Zhang, and S.H. Snyder. 1999. Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends in Pharmacological Sciences 20:171-81.
4. Thiemermann, C., J. Bowes, F.P. Myint, and J.R. Vane. 1997. Inhibition of the activity of poly(ADP-ribose) synthase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-83.
|
